Intracranial treatment for solitary prostatic adenocarcinoma brain metastasis is curative

Solitary metastasis to the brain from prostate cancer is rare. We present a young patient with a prostate-specific antigen value of 26 ng/dL and pathologic Gleason score 4 + 5 = 9 prostatic adenocarcinoma who developed a solitary cerebral metastasis 4 years after radical prostatectomy. With aggressive treatment involving resection of the solitary metastasis and use of local brachytherapy, the patient remains with an undetectable PSA level and without evidence of disease 5 years later. Our experience suggests that delayed solitary metastasis may be curable with treatment.